- About ELS
- Therapeutic Areas
- Operational Metrics
- Contact Us
As per data recorded from the year Jan 2017 to Jan 2019 we have observed that, India’s growing incidence of Hypertensive and Diabetic patients contribute to a great prevalence of kidney related diseases. It is estimated that every 5th patient with high blood pressure and every 7th patient with diabetes, will develop Chronic Kidney Disease (CKD). Currently, the rate of Chronic Kidney Disease (CKD) in India is estimated at 0.2%. This translates into approximately 20,00,000 patients. In many cases, this progresses to Chronic Renal Failure (CRF), affecting over 2,00,000 patients each year.
Other common kidney related disorders in India are Urolithiasis, Urinary Tract Infections, Glomerulopathies, and disorders regarding body fluids and electrolytes. The growing incidence of hypertension and diabetes in India has also contributed significantly to the prevalence of kidney related diseases. Diabetes and hypertension account for 40-60% cases of chronic kidney disease (CKD). The increase in cases of diabetes and hypertension cases in urban India has resulted in an increase in the number of people suffering from kidney disease (nearly 17%). Out of this, nearly 6% have stage III kidney disease which needs medical attention. The yearly incidence of end stage renal disease (ESRD) in India is approximately 150–200 per million people.
We have conducted a number of studies in the area of nephrology and we are confident that we can assist you with your next study. Excel Life Sciences (ELS) has developed one of the most experienced and sophisticated networks of nephrology investigators and investigative sites in India. Each has deep access to a large and diverse patient pool and sees more than 100 new patients every month. Using our databases of detailed site information, demographics and epidemiology data we can quickly determine if India is the right fit for your study.
In addition, ELS can quickly mobilize a team of experienced project managers to conduct a study feasibility analysis and determine the appropriate sites and availability of patients. We ensure that nephrology clinical trials are conducted according to ICH-GCP guidelines and meet the highest standards of ethics and integrity.